Updated:
Advanced Research Projects Agency for Health
ARPA-H was authorized in March 2022 and formally established later that year as an independent agency within the National Institutes of Health.
Advanced Research Projects Agency for Health
ARPA-H was authorized in March 2022 and formally established later that year as an independent agency within the National Institutes of Health. Renee Wegrzyn, a biologist and former program manager at the Defense Advanced Research Projects Agency, became its first director in October 2022. The agency was seeded with $1 billion in initial funding and subsequently appropriated an additional $1.5 billion, creating a five-year deployment window unusual in civilian health research. The agency operates through three core focus areas: Health Science Futures, Scalable Solutions, and Proactive Health. It funds work across gene editing delivery, cell-based therapies, mRNA platform optimization, antimicrobial resistance, and surgical robotics. Unlike traditional NIH grants, ARPA-H uses Other Transaction Agreements that allow for-profit companies, academic teams, and nonprofit labs to accept funding with more flexible intellectual property and reporting terms. Initial awards have gone to teams at MIT, Emory University, and Rice University for work on programmable intracellular sensors and next-generation cancer vaccines. Wegrzyn has structured the agency with term-limited program managers who wield significant authority to define programs, select performers, and redirect funds — a model drawn directly from DARPA. In October 2023, ARPA-H launched the Advanced Analysis for Precision Cancer Therapy initiative to build machine-learning models that predict tumor responses to single drugs and combination regimens (per the agency, October 2023). The agency also announced the NITRO program targeting osteoarthritis, aiming to develop interventions that regenerate joint tissue rather than manage pain. ARPA-H is not a family office, fund, or investment vehicle. It is a funding agency that selects projects where technical risk would deter standard venture capital or NIH study sections. Its structural difference from the broader NIH is operational speed and tolerance for failure: program managers have fewer than six years to move an idea from concept to a working prototype or clinical proof, after which they rotate out. This forces a cadence of launch-and-learn that traditional grant-making institutions structurally avoid.
General information
Firm type
other
Year founded
2022
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Washington
Corporate office
Washington, DC, United States
Principals
Renee Wegrzyn
Director
Sector focus
Frequently asked questions
Who runs investment decisions at ARPA-H?
Director Renee Wegrzyn sets the agency's strategic priorities, but individual program managers design and execute specific programs. These term-limited managers identify research gaps, write program solicitations, select performer teams, and have authority to modify or terminate projects based on milestone results. Governance and selection processes are outlined in the agency's authorizing statute and published funding announcements.
Is ARPA-H part of the NIH?
Yes, ARPA-H is established as an independent agency within the National Institutes of Health. It was authorized by Congress in the 2022 appropriations bill and reports to the Secretary of Health and Human Services, not the NIH Director directly. This structure gives it budgetary and operational independence from standard NIH peer-review processes.
What investment stages does ARPA-H typically target?
ARPA-H funds translational research — the chasm between basic science discoveries and clinically deployable products. Projects range from early proof-of-concept to preclinical validation and early-stage human trials. The agency intentionally avoids work that could be funded through standard NIH R01 grants or that has near-term commercial viability attractive to venture capital.
Does ARPA-H take equity in companies it funds?
No. ARPA-H does not take equity positions, nor does it expect a financial return. Its funding instruments are grants, cooperative agreements, and Other Transaction Agreements that may include milestone-based payments. Intellectual property terms are negotiated per award, generally allowing performers to retain ownership while granting the government certain use rights.
Which sectors does ARPA-H explicitly avoid?
The agency is structured to avoid incremental or near-certain advances. It does not fund late-stage clinical trials outside exceptional circumstances, nor does it support work that existing pharmaceutical development pipelines or NIH institutes are expected to pursue. It has no mandate in non-health technologies, defense-specific medical countermeasures, or pure basic science without a translational path.
How does ARPA-H source proposals?
ARPA-H program managers define program areas and publish Broad Agency Announcements, targeted solicitations, and prize challenges. Proposals are accepted from universities, nonprofit research institutes, and companies of any size. The agency also holds proposer days and outreach events to shape programs before formal solicitations are released.
What is ARPA-H's known posture on co-investment alongside external funders?
The agency actively encourages co-funding arrangements with other government entities, philanthropic foundations, and private investors. Several programs require or incentivize cost-sharing from performers or external partners. ARPA-H has publicly stated a goal of bridging projects from government support into commercial pathways where private capital can fund later development and scale-up.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: